ArticleJournal of neuro-oncology2000
The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.
Article in Journal of neuro-oncology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 24 citations in OpenAlex.
- Determination of genetic aberrations and novel transcripts involved in the pathogenesis of oligodendroglioma using array comparative genomic hybridization and next generation sequencing.Oncology letters · 2019Article
- Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Cavernous angioma within the context of anaplastic oligodendroglioma: case report and review of the literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Review
- Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas.Journal of neuro-oncology · 2006Article
- Immunohistochemical markers for prognosis of oligodendroglial neoplasms.Journal of neuro-oncology · 2002Article
- VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma.World journal of gastroenterology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligodendrogliomas continue to generate considerable difficulties in identifying prognostic factors, including single histopathological patterns. Among the latter, vascular productive changes have been intensively examined but the obtained results appear to be controversial. Numerous studies have revealed an indisputable importance of vascular endothelial growth factor (VEGF) immunoreactivity for malignant progression of astrocytomas but the data regarding oligodendrogliomas are heterogeneous. Ninety-one patients with oligodendroglioma were examined retrospectively for VECF immunoexpression. The results demonstrated significant preponderance of intracellular VEGF expression for WHO grade III tumors. Nevertheless, VEGF staining patterns correlated with both progression-free and overall survival only in univariate, but not in multivarite analysis. Only WHO tumor grade was found to be an independent prognostic factor for oligodendroglioma outcome. Therefore, it seems unlikely that VEGF immunohistochemistry will be of value in assessing individual oligodendroglioma prognosis, especially for determining of both progression-free and overall survival from histologically low-grade tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.